A Phase 3 interventional study of Gabapentin Extended-Release (G-ER) 1200 mg and Gabapentin Extended-Release (G-ER) 1800 mg in Hot Flashes, sponsored by Depomed. Completed at 45 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-03-07.
Sponsored by Depomed · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gabapentin in Hot Flashes — none open to participants now, none under way, none of them phase 3. Gabapentin · Hot Flashes.
Among the 11 studies testing gabapentin in Hot Flashes, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 6th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 11 studies testing gabapentin in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 541 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 160 across the 10 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 7 most frequent:
Depomed is the lead sponsor of 14 studies on the registry; none are open to participants now.
Depomed has 4 studies filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing gabapentin in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Depomed's Gabapentin Extended Release (G-ER) is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.
The primary study objective is to assess the efficacy of G-ER dosed in either of the following regimens:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other Inclusions apply.
Exclusion Criteria:
Other Exclusions apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gabapentin extended-release (G-ER) 1200 mg
Drug: Gabapentin Extended-Release (G-ER) 1200 mg
Gabapentin extended-release (G-ER) 1800 mg
Drug: Gabapentin Extended-Release (G-ER) 1800 mg
Placebo 1200 mg or 1800 mg
Drug: Placebo
G-ER 1200 mg daily dosage given as two 600-mg tablets.
Also known as: Gabapentin
G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
Also known as: Gabapentin
Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Change from baseline in average daily frequency of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.
Time frame: From baseline to 4 weeks
Change From Baseline in Average Daily Frequency of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Change from baseline in average daily frequency of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.
Time frame: Form baseline to 12 weeks
Change From Baseline in Average Daily Severity Score of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Change from baseline in average daily severity score of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale where 1=Mild, 2=Moderate, and 3=Severe.
Time frame: From baseline to 4 weeks
Change From Baseline in Average Daily Severity Score of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Change from baseline in average daily severity score of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale were 1=Mild, 2=Moderate, and 3=Severe.
Time frame: From baseline to 12 weeks
| Milestone | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill |
|---|---|---|---|
| Started | 174 | 181 | 177 |
| Completed | 112 | 126 | 135 |
| Not completed | 62 | 55 | 42 |
| Withdrew: Adverse event | 28 | 20 | 7 |
| Withdrew: Lack of efficacy | 8 | 4 | 9 |
| Withdrew: Protocol violation | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 | 1 |
| Withdrew: Withdrawal by subject | 12 | 12 | 12 |
| Withdrew: Not specified or missing data | 9 | 18 | 12 |
Change from baseline in average daily frequency of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.
| Moderate or severe hot flashes | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill |
|---|---|---|---|
| Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo | -6.8 (-7.37 to -6.13) | -7.3 (-7.89 to -6.71) | -5.8 (-6.41 to -5.18) |
Change from baseline in average daily frequency of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.
| Moderate or severe hot flashes | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill |
|---|---|---|---|
| Change From Baseline in Average Daily Frequency of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo | -7.4 (-8.10 to -6.73) | -7.4 (-8.04 to -6.74) | -6.9 (-7.53 to -6.18) |
Change from baseline in average daily severity score of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale where 1=Mild, 2=Moderate, and 3=Severe.
| Score on a numerical scale | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill |
|---|---|---|---|
| Change From Baseline in Average Daily Severity Score of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo | -0.5 (-0.68 to -0.41) | -0.6 (-0.74 to -0.48) | -0.3 (-0.42 to -0.15) |
Change from baseline in average daily severity score of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale were 1=Mild, 2=Moderate, and 3=Severe.
| Score on a numerical scale | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill |
|---|---|---|---|
| Change From Baseline in Average Daily Severity Score of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo | -0.7 (-0.91 to -0.58) | -0.7 (-0.90 to -0.59) | -0.5 (-0.71 to -0.38) |
Collected over Total of 26 weeks: from randomization through 1 week after study completion (week 25).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-ER 1200 mg | — | 2/174 (1.1%) | 148/174 (85.1%) |
| G-ER 1800 mg | — | 6/181 (3.3%) | 167/181 (92.3%) |
| Sugar Pill | — | 4/177 (2.3%) | 65/177 (36.7%) |
| Event | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill |
|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/174 | 1/181 | 0/177 |
| Gastroesophageal reflux disease exacerbationGastrointestinal disorders | 1/174 | 0/181 | 0/177 |
| Abdominal herniaGastrointestinal disorders | 0/174 | 0/181 | 1/177 |
| Cerebrovascular disorderNervous system disorders | 0/174 | 0/181 | 1/177 |
| Chest painGeneral disorders | 0/174 | 0/181 | 1/177 |
| Coronary artery diseaseCardiac disorders | 0/174 | 0/181 | 1/177 |
| Malignant lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/174 | 1/181 | 0/177 |
| Nerve compressionNervous system disorders | 0/174 | 1/181 | 0/177 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/174 | 1/181 | 0/177 |
| Rib fractureInjury, poisoning and procedural complications | 0/174 | 1/181 | 0/177 |
| Event | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill |
|---|---|---|---|
| DizzinessNervous system disorders | 41/174 | 35/181 | 5/177 |
| SomnolenceNervous system disorders | 23/174 | 35/181 | 4/177 |
| HeadacheNervous system disorders | 15/174 | 17/181 | 10/177 |
| NauseaGastrointestinal disorders | 12/174 | 16/181 | 7/177 |
| NasopharyngitisInfections and infestations | 14/174 | 11/181 | 7/177 |
| VomitingGastrointestinal disorders | 3/174 | 13/181 | 4/177 |
| FlatulenceGastrointestinal disorders | 11/174 | 7/181 | 2/177 |
| Upper respiratory tract infectionInfections and infestations | 11/174 | 10/181 | 10/177 |
| FatigueGeneral disorders | 9/174 | 9/181 | 3/177 |
| Back painMusculoskeletal and connective tissue disorders | 4/174 | 5/181 | 9/177 |
| Age Continuous(Years) | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|---|
| Mean | 52.9 ± 5.3 | 52.9 ± 6.5 | 53.0 ± 6.6 | 52.9 ± 6.2 |
| Age, Customized(Participants) | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|---|
| <65 years | 170 | 176 | 170 | 516 |
| >=65 years | 4 | 5 | 7 | 16 |
| Sex: Female, Male(Participants) | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|---|
| Female | 174 | 181 | 177 | 532 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|---|
| White | 121 | 125 | 111 | 357 |
| Black | 39 | 37 | 50 | 126 |
| Asian | 1 | 1 | 1 | 3 |
| Hispanic | 12 | 13 | 12 | 37 |
| Other | 1 | 5 | 3 | 9 |
| Number of hot flashes in 24-hour period(Hot flashes) | G-ER 1200 mg | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|---|
| Moderate hot flashes | 6.1 ± 4.5 | 6.2 ± 5.7 | 6.3 ± 5.6 | 6.2 ± 5.3 |
| Severe hot flashes | 6.4 ± 4.6 | 7.4 ± 5.8 | 7.1 ± 5.9 | 7.0 ± 5.5 |
The record gives a start of Sep 2008, a primary completion of Aug 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Depomed